ESC 365 - A multicenter, randomized, double-blind, placebo-controlled, parallel group study on the safety and efficacy of istaroxime for pre-cardiogenic shock

Open Access

A multicenter, randomized, double-blind, placebo-controlled, parallel group study on the safety and efficacy of istaroxime for pre-cardiogenic shock

Session: Late-breaking science in acute heart failure

Topic: Pharmacotherapy

Speaker: Doctor J. Biegus (Wroclaw, PL)

Event: Heart Failure 2025

Congress Presentation

Add to my library

About the speaker

Doctor Jan Biegus

Institute of Heart Diseases, Wroclaw (Poland)

4 presentations

1 follower

6 more presentations in this session

Discussant panel

Kidney function trajectories before and after heart failure hospitalization in heart failure with reduced ejection fraction: findings from clinical trials and real-world data

Speaker: Professor N. Girerd (Nancy, FR)

Sodium chloride vs. glucose solute as a volume replacement therapy for more effective decongestion in acute heart failure

Speaker: Doctor J. Biegus (Wroclaw, PL)

Combination oral acetazolamide and intravenous furosemide on acute decompensated heart failure

Speaker: Mrs I. Farissa (Semarang, ID)

Impact of a urinary-sodium driven algorithm to optimize natriuresis in patients with ADHF: the FASTR trial

Speaker: Associate Professor K. Damman (Groningen, NL)

Access the full session

Late-breaking science in acute heart failure

Speakers: Doctor J. Biegus, Professor N. Girerd, Doctor J. Biegus, Mrs I. Farissa, Associate Professor K. Damman

About the event

Heart Failure 2025

17 May - 20 May 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources

Explore sponsored resources